URL of this page: https://medlineplus.gov/druginfo/meds/a622075.html

Mirvetuximab soravtansine-gynx Injection

pronounced as (mir" ve tux' i mab)

IMPORTANT WARNING:

Mirvetuximab soravtansine-gynx may cause damage to your eyes. If you experience any of the following symptoms, call your doctor immediately: vision changes, dry eye, light sensitivity, eye pain, eye redness, excess tearing or discharge from the eye, difficulty opening the eyelid because of pain, blurred vision, or feeling like something is in your eye.

Keep all appointments with your doctor. Your doctor will send you for an eye exam before and during mirvetuximab soravtansine-gynx treatment to monitor your eyes during therapy.

Your doctor may give you eye drops to take before you start and during treatment with mirvetuximab soravtansine-gynx to reduce the risk of eye toxicity from occurring. You should avoid use of contact lenses during treatment with mirvetuximab unless told otherwise by your provider. If eye symptoms develop, your doctor may need to stop or change your mirvetuximab soravtansine-gynx treatment to prevent any further damage to the eyes.

Why is this medication prescribed?

Mirvetuximab soravtansine-gynx injection is used to treat certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Mirvetuximab soravtansine-gynx is in a class of medications called folate receptor alpha-directed antibody and microtubule inhibitor conjugates. It works by killing cancer cells.

How should this medicine be used?

Mirvetuximab soravtansine-gynx injection comes as a solution (liquid) to be given by a doctor or nurse at a clinic or hospital as an intravenous (into the vein) infusion. It is usually given once every 3 weeks. Your doctor will decide how many cycles you should receive. Before each infusion of mirvetuximab soravtansine-gynx, you will receive medications to prevent infusion-related reactions, nausea and vomiting. Your doctor or nurse will monitor you during the infusion and may adjust the infusion rate or dose of the current infusion or any future infusion based on any side effects you may experience.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving mirvetuximab soravtansine-gynx injection,

  • tell your doctor and pharmacist if you are allergic to mirvetuximab soravtansine-gynx, any other medications, or any of the ingredients in mirvetuximab soravtansine-gynx injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take while taking mirvetuximab soravtansine-gynx injection. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had vision or eye problems or kidney or liver disease.
  • tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are receiving mirvetuximab soravtansine-gynx injection. You should use effective birth control to prevent pregnancy during your treatment with mirvetuximab soravtansine-gynx and for at least 7 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while receiving mirvetuximab soravtansine-gynx, call your doctor immediately. Mirvetuximab soravtansine-gynx may harm the fetus.
  • tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while receiving mirvetuximab soravtansine-gynx and for at least 1 month after your final dose.

What special dietary instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What should I do if I forget a dose?

If you miss an appointment to receive a mirvetuximab soravtansine-gynx injection, call your doctor as soon as possible.

What side effects can this medication cause?

Mirvetuximab soravtansine-gynx injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • feeling tired
  • diarrhea
  • nausea
  • abdominal pain
  • constipation
  • muscle weakness or spasms

Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:

  • trouble breathing, cough, shortness of breath, or chest pain
  • new or worsening tingling or numbness in your hands or feet or muscle weakness

Mirvetuximab soravtansine-gynx injection may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What other information should I know?

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to mirvetuximab soravtansine-gynx injection.

Before having any laboratory test, tell your doctor and the laboratory personnel that you are receiving mirvetuximab soravtansine-gynx injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Brand names

  • Elahere®
Last Revised - 12/15/2022